Loss of PTEN in High Grade Advanced Stage Triple Negative Breast Ductal Cancers in African American Women

Publication date: Available online 27 March 2018
Source:Pathology - Research and Practice
Author(s): Farhan Khan, Ashwini Esnakula, Luisel J Ricks-Santi, Rabia Zafar, Yasmine Kanaan, Tammey Naab
IntroductionPTEN is a tumor suppressor gene that inhibits cell proliferation by inhibiting the phosphoinositide 3- kinase (PI3 K) signaling pathway. The significance of PTEN mutations resulting in variable PTEN expression and their impact on prognosis of breast cancer is not well established. The objective of our study was to correlate the immunohistochemical expression of PTEN in the four major subtypes of breast carcinoma (Luminal A, Luminal B, HER2 positive, and Triple Negative) in a population of 202 African-American (AA) females with other clinicopathological factors.Materials and MethodsTissue microarrays (TMAs) were constructed from FFPE tumor blocks from primary ductal breast carcinomas in 202 African-American females. Five micrometer sections were stained with a mouse monoclonal antibody against PTEN. The sections were evaluated for the intensity of cytoplasmic and nuclear reactivity. Bivariate analysis was done via χ2 analysis and survivability data was calculated via the generation of Kaplan-Meier curves (SPSS v19).ResultsLoss of PTEN expression was associated with ER negative (p = 0.021), PR negative (p = 0.024) and triple negative (p = 0.0024) breast ductal cancers. It was marginally associated with distant metastasis (p = 0.074). There was no association between PTEN loss and recurrence-free survival or overall survival.ConclusionIn our study, a statistically significant association between PTEN loss and the triple negative breast cancers (TNBC) was found in AA women. PTEN inhibits PI3 K resulting in decreased activation of downstream effector, mammalian target of rapamycin (mTOR). Loss of PTEN results in cell proliferation through activation of mTOR. Targeted therapy with mTOR inhibitors might be useful in the treatment of TNBC.



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2GjIaSF